University at Buffalo biotech firm partners with South Korea-based vaccine leader to create novel therapies and vaccines based on its proprietary biotech platform.
University at Buffalo spinout company Pop Biotechnologies has received a $2.4 million National Institutes of Health grant to pursue an immunotherapy treatment for Alzheimer's disease.
The Alzheimer’s immunotherapy program is part of a broader initiative also involving EuPOP Life Sciences – a joint venture between POP BIO and South Korea-based global vaccine leader EuBiologics Co., Ltd.
